Literature DB >> 15150901

Risk of death due to hepatocellular carcinoma among drinkers and ex-drinkers. Univariate analysis of JACC study data.

Itsuro Ogimoto1, Akira Shibata, Youichi Kurozawa, Takayuki Nose, Takesumi Yoshimura, Hiroshi Suzuki, Nobuo Iwai, Ritsu Sakata, Yuki Fujita, Shoko Ichikawa, Katsuhiro Fukuda, Akiko Tamakoshi.   

Abstract

Hazard ratios (HR) of death due to hepatocellular carcinoma (HCC) were analyzed by gender and age strata (40-59 and 60-79) among drinkers and ex-drinkers in 66,974 eligible subjects from a a large cohort of male and female subjects aged 40-79 years, based on information about several drinking related characteristics. The HR of dying from HCC for ex-drinkers was 4 to 8 times higher than for those who had never consumed alcohol at the baseline survey. When the subjects were restricted to those without history of liver disease (LD), the HR was still high for ex-drinkers among younger males, though the difference was not statistically significant. It appeared that the earlier drinking habits were established, the higher the HR, especially for younger males without LD. Among total current drinkers, the amount ingested per occasion and the cumulative amount ingested at the baseline did not show significantly increased HRs. Among subjects without LD, larger amounts ingested per occasion and larger cumulative amount seemed to have higher HRs in older male current drinkers. Frequent drinking and later age (50 to 79) at cessation of drinking were associated with higher HRs among both genders and both age strata. After restricting the analysis to subjects without LD, many of these increased HRs remained among males. The results suggested that the association between alcohol drinking history and HR of HCC differs depending on the presence of LD. Major confounders other than age and gender associated with both drinking and HCC, e.g. smoking, hepatitis virus infection, or history of diabetes, were not considered in this analysis, and the observed associations might be confounded by any of these factors. To clarify the net association between alcohol drinking and HCC, further analysis is needed to control potential confounders, including past history of liver disease, and to consider probable effect modifiers.

Entities:  

Mesh:

Year:  2004        PMID: 15150901     DOI: 10.2739/kurumemedj.51.59

Source DB:  PubMed          Journal:  Kurume Med J        ISSN: 0023-5679


  6 in total

1.  p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies.

Authors:  Xi Chen; Fei Liu; Bo Li; Yong-Gang Wei; Lv-Nan Yan; Tian-Fu Wen
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

2.  Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis.

Authors:  Yong-Gang Wei; Fei Liu; Bo Li; Xi Chen; Yu Ma; Lv-Nan Yan; Tian-Fu Wen; Ming-Qing Xu; Wen-Tao Wang; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

Review 3.  How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature.

Authors:  Gawain A Heckley; Johan Jarl; Benedict O Asamoah; Ulf G-Gerdtham
Journal:  BMC Cancer       Date:  2011-10-13       Impact factor: 4.430

4.  Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C.

Authors:  Clement Ibi Mboto; Angela Davies-Russell; Mark Fielder; Andrew Paul Jewell
Journal:  Int Semin Surg Oncol       Date:  2005-10-04

Review 5.  Experimental Models to Define the Genetic Predisposition to Liver Cancer.

Authors:  Rosa M Pascale; Maria M Simile; Graziella Peitta; Maria A Seddaiu; Francesco Feo; Diego F Calvisi
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

Review 6.  Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.

Authors:  Inga Hochnadel; Uta Kossatz-Boehlert; Nils Jedicke; Henrike Lenzen; Michael P Manns; Tetyana Yevsa
Journal:  Hum Vaccin Immunother       Date:  2017-11-07       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.